about
Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injectionRisk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) studyPatient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in Central Europe and East Asia.Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind studyPredictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study.Antidepressant medication treatment patterns in Asian patients with major depressive disorderShould Unexplained Painful Physical Symptoms be Considered within the Spectrum of Depressive Symptoms?Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review.Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study.Predictors of duloxetine adherence and persistence in patients with fibromyalgia.Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting.Health care costs before and after diagnosis of depression in patients with unexplained pain: a retrospective cohort study using the United Kingdom General Practice Research Database.Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East AsiaImpact of anxiety symptoms on outcomes of depression: an observational study in Asian patients.Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies.Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia.Schizophrenia Outpatient Health Outcomes study: twelve-month findingsIncidence of diabetic peripheral neuropathic pain in primary care - a retrospective cohort study using the United Kingdom General Practice Research DatabaseEmpirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.Real-world treatment patterns and opioid use in chronic low back pain patients initiating duloxetine versus standard of care.Sex differences in the course of schizophrenia across diverse regions of the world.Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder.Lost in transition: A review of the unmet need of patients with attention deficit/hyperactivity disorder transitioning to adulthood.Real-world Effectiveness of Antipsychotics for the Treatment of Negative Symptoms in Patients with Schizophrenia with Predominantly Negative Symptoms.Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study.Duloxetine for the treatment of painful diabetic peripheral neuropathy in Venezuela: economic evaluation.Costs associated with treatment of chronic low back pain: an analysis of the UK General Practice Research Database.Regional differences in treatment response and three year course of schizophrenia across the world.Factors predicting hostility in outpatients with schizophrenia: 36-month results from the SOHO study.Factors associated with and impact of pain persistence in Asian patients with depression: a 3-month, prospective observational study.Which somatic symptoms are associated with an unfavorable course in Chinese patients with major depressive disorder?Caregiving for patients with Alzheimer's disease or dementia and its association with psychiatric and clinical comorbidities and other health outcomes in Brazil.Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.The economic burden of advanced gastric cancer in Taiwan.Chinese patients with major depression: Do concomitant pain symptoms affect quality of life independently of severity of depression?Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia.Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice.
P50
Q33817737-E85B93F0-96C6-4916-B272-CA4CF9435C96Q34343697-2C54D06D-B742-4D62-A299-1E031C3F8695Q34446828-9EC937BD-03D6-4633-969D-BD9501E09606Q34498541-C6A71B29-DCCA-40DF-BF11-BAE3206F6678Q34990923-EB530AB3-182C-4C38-833C-56602A17A82BQ35024270-B03695B2-942B-4FF0-8726-0E2214C47CFFQ35186024-7C948E01-9A01-4410-A83B-F429C75DBA45Q35338187-D6F182C7-7AA3-4A54-B45A-DDFA2BA74E1EQ35714775-544A1B1B-79DD-4291-BF11-52BFC3DB8150Q35736374-23206BC8-2B9F-471F-94A7-A6E3A0E80D88Q36084689-E81AAD68-CF3C-4964-8D1E-DC6CB4D589F2Q36208461-E4B661EF-6887-4F0B-8B19-659C2F08F94CQ36555090-E5D3CA03-39D1-4609-BD4C-477D305A9DFBQ36627458-879E66B2-6A65-4874-818E-08CB644C26ACQ36802781-8DC53337-65E4-49EB-8F81-992DE2E676B6Q36957237-C87E2653-C846-45F0-8E85-7B0B2F6428C1Q37159781-E0B693A5-820C-4EB3-887B-F80D416802B5Q37225350-E9DCBA01-D369-451A-8C4C-AF872F39A1C1Q37300879-AF151E24-AD1C-41A7-A7AD-661E89E46F22Q37300906-A0E55220-159B-4013-8644-EF07EE9EF2BEQ37302364-8A7A2C62-B2FA-414D-99A8-BD38FE59ABCBQ37350354-EF55BF86-0DF9-4457-BDEE-65FC93063844Q37423268-A35771A6-A67F-4E70-8E3F-C36F6D8713DDQ38707913-AA3A21C5-7EC5-4585-BBB9-0CFD1B6FDB13Q38934894-D2C26D7F-10A2-4BC9-9859-9460294ECEB3Q38957131-DE35F55A-B9E1-4DBC-8F51-22BAEA424C3DQ39048817-5F675B28-4A0E-4A7E-B077-E0C116C258B2Q39182139-641A8FA4-39CE-49E7-AA39-297679E07908Q39240700-69837B2C-431E-4581-A64D-A722FFF1E969Q39310638-27E45A2F-BA4C-4B09-A4CA-264AEF5AE40DQ39416498-062D7A0E-7635-42BD-B42D-7096F9C42507Q40515464-69516C3F-D79B-4C1D-A42C-3EDE5DED45ACQ40865825-E7EB40F3-DB67-459F-B386-028774B0E9F8Q40901921-387306E8-12D7-4180-A080-75CDA9275F15Q41161590-E9D9C573-A48D-49CA-A7A6-D2217A7E2439Q41711794-99D2C4B6-3A51-4B47-8886-733D02196641Q41757841-E1FFEE3E-1E37-47DB-9A7C-B14096C764B7Q42171194-A1A94BDE-CE4F-45C7-8533-B9AA0CFD678EQ42918766-73CA726E-1195-446F-902E-38C7D1D039E6Q43041213-6E4B05C9-E13E-4320-B5B6-0CE11CA7A52C
P50
name
Diego Novick
@en
Diego Novick
@nl
type
label
Diego Novick
@en
Diego Novick
@nl
prefLabel
Diego Novick
@en
Diego Novick
@nl